Violets’ cyclotides could revolutionize glioblastoma treatment by boosting chemotherapy efficacy, now advancing to mouse model testing. Glioblastoma is one of the deadliest brain diseases known. More than 45% of brain cancers are gliomas. Only half of glioblastoma patients respond to the FDA-approved chemotherapy Temozolomide (TMZ). Even for those patients, the cancer cells quickly evolve resistance. […]
Source link